Time filter

Source Type

Alicante, Spain

Lledo B.,Instituto Bernabeu Biotech | Ortiz J.A.,Instituto Bernabeu Biotech | Llacer J.,Instituto Bernabeu of Fertility and Gynecology | Bernabeu R.,Instituto Bernabeu Biotech | Bernabeu R.,Instituto Bernabeu of Fertility and Gynecology
Pharmacogenomics | Year: 2014

Effective controlled ovarian stimulation (COS) is crucial for IVF outcome. Ovarian response to follicle-stimulating hormone, however, varies widely among women undergoing ovarian stimulation. Advance identification of patients who will elicit a poor or high response to standard treatment would be of great clinical benefit for such patients. Application of pharmacogenetics to ovarian response may predict stimulation success but also help in the adjustment and design of doses prior to treatment. Different studies have examined the impact of variations in follicle-stimulating hormone receptor, biochemical pathways involved in estrogen production and action, folliculogenesis and other aspects. Recently, gene-association studies have tried to identify a number of genetic variations affecting interindividual variability in COS. © 2014 Future Medicine Ltd. Source

Lledo B.,Instituto Bernabeu Biotech | Turienzo A.,Instituto Bernabeu Biotech | Ortiz J.A.,Instituto Bernabeu Biotech | Morales R.,Instituto Bernabeu Biotech | And 4 more authors.
Journal of Assisted Reproduction and Genetics | Year: 2014

Purpose: Investigate whether R72P on p53 gene polymorphism has a higher prevalence among women with a history of recurrent implantation failure (RIF) and pregnancy loss (RPL) and its influence in their IVF cycle outcome. Material and methods: tjhep53 polymorphism R72P has been studied in 181 women. The control group included 83 oocyte donors. In the study group 98 women were included: 44 with RIF and 54 with RPL. From the study group, 76 patients underwent IVF-cycles (55 RPL and 21 RIF). Results: The frequency of PP genotypes on p53 among RIF was 11.4 % compared with 18.5 % for RPL and 6 % in controls (p<0.01). There were no significant differences with respect to patient characteristics. Significant differences were reported in pregnancy rate (69.4 % for RR/RP and 33.3 % for PP; p<0.05), embryo implantation rate (33.3 % for RR/RP and 7.3 % for PP; p<0.05) and ongoing pregnancy rate (53.1 % for RR/RP and 14.3 % for PP; p<0.05) among RIF and RPL. Conclusions: This investigation reveals that in RIF and RPL patients R72P on p53 gene is more prevalent than fertile population. Moreover, patients carrying a PP genotype on p53 codon 72 will have less chance to achieve an ongoing pregnancy. This information together with some additional markers will allow development of diagnostic tests for detects risk for RIF and RPL before infertility treatment is initiated. © 2013 Springer Science+Business Media. Source

Lledo B.,Instituto Bernabeu Biotech | Guerrero J.,Instituto Bernabeu of Fertility and Gynecology | Turienzo A.,Instituto Bernabeu Biotech | Ortiz J.A.,Instituto Bernabeu Biotech | And 5 more authors.
Pharmacogenetics and Genomics | Year: 2013

Objective: The aim of this study was to investigate whether N680S FSHR polymorphism has a predictive value for the ovarian response to stimulation with gonadotropins and cycle outcome in our egg donor program. Methods: The oocyte donor candidates were selected according to the Instituto Bernabeu egg donation program requirements and ASRM and ESHRE guidelines for oocyte donation. The FSHR polymorphism N680S was studied in 145 oocyte donors. All donors underwent controlled ovarian hyperstimulation (COH) (n=355) using urinary follicle-stimulating hormone in a GnRH antagonist protocol and receiving a GnRH agonist triggering. The main outcome measures were oocyte yield, days of stimulation, gonadotropin doses, biochemical pregnancy, ongoing pregnancy, and miscarriage rates. Results: Significant differences were reported in the antral follicle count (16.5±5.0 for NN, 14.5±4.7 for NS, and 14.1±3.8 for SS), number of eggs retrieved (21.5±9.2 for NN, 18.5±8.2 for NS, and 19.8±8.9 for SS), and gonadotropin doses (2098.5±639.4 IU for NN, 2023 ±490.1 IU for NS, and 2149.5±552.3 IU for SS) between the genotypes. The clinical outcome was not affected by the N680S polymorphism of the FSHR gene in the egg donors. Conclusion: In a population of fertile egg donors, the FSHR gene polymorphism at position 680 is associated with different ovarian responses to COH. The genotype of the FSHR gene is an important factor for determining the prognosis of the COH cycles in normo-ovulatory fertile women. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source

Discover hidden collaborations